Doripenem: an expected arrival in the treatment of infections caused by multidrug-resistant Gram-negative pathogens

Bibliography

• Anderson DL. Doripenem. Drugs Today (Barc) 2006;42(6):399-404
   PubMed Web of Science ®Google Scholar
• Johnson & Johnson announces agreement to acquire Peninsula Pharmaceuticals, Inc. Available from: http://www.investor.jnj.com/releaseDetail.cfm?ReleaseID=160602&year=2005&textOnly=false
   Google Scholar
• Giamarellou H. Prescribing guidelines for severe Pseudomonas infections. J Antimicrob Chemother 2002;49(2):229-33
   PubMed Web of Science ®Google Scholar
• Kipnis E, Sawa T, Wiener-Kronish J. Targeting mechanisms of Pseudomonas aeruginosa pathogenesis. Med Mal Infect 2006;36(2):78-9
   PubMed Web of Science ®Google Scholar
• Carmeli Y, Troillet N, Eliopoulos GM, Samore MH. Emergence of antibiotic-resistant Pseudomonas aeruginosa: comparison of risks associated with different antipseudomonal agents. Antimicrob Agents Chemother 1999;43(6):1379-82
   PubMed Web of Science ®Google Scholar
• Micek ST, Lloyd AE, Ritchie DJ, et al. Pseudomonas aeruginosa bloodstream infection: importance of appropriate initial antimicrobial treatment. Antimicrob Agents Chemother 2005;49(4):1306-11
   PubMed Web of Science ®Google Scholar
• Anonymous. National Nosocomial Infections Surveillance (NNIS) System Report, data summary from January 1992 through June 2004, issued October 2004. Am J Infect Control 2004;32(8):470-85
   PubMed Web of Science ®Google Scholar
• Rossolini GM, Mantengoli E. Treatment and control of severe infections caused by multiresistant Pseudomonas aeruginosa. Clin Microbiol Infect 2005;11(Suppl 4):17-32
   PubMed Web of Science ®Google Scholar
• The database of Meropenem Yearly Susceptibility Test Information Collection (MYSTIC) Program, provides information regarding resistance rates across several countries that participate in the surveillance program. Available from: http://www.infectionacademy.org/surveillance/ [Accessed on 18 November 2007]
   Google Scholar
• Turner PJ. Meropenem activity against European isolates: report on the MYSTIC (Meropenem Yearly Susceptibility Test Information Collection) 2006 results. Diagn Microbiol Infect Dis 2008;60(2):185-92
   PubMed Web of Science ®Google Scholar
• Abbo A, Navon-Venezia S, Hammer-Muntz O, et al. Multidrug-resistant Acinetobacter baumannii. Emerg Infect Dis 2005;11(1):22-9
   PubMed Web of Science ®Google Scholar
• Go ES, Urban C, Burns J, et al. Clinical and molecular epidemiology of acinetobacter infections sensitive only to polymyxin B and sulbactam. Lancet 1994;344(8933):1329-32
   PubMed Web of Science ®Google Scholar
• Abbo A, Carmeli Y, Navon-Venezia S, et al. Impact of multi-drug-resistant Acinetobacter baumannii on clinical outcomes. Eur J Clin Microbiol Infect Dis 2007;26(11):793-800
   PubMed Web of Science ®Google Scholar
• McDonald LC. Trends in antimicrobial resistance in health care-associated pathogens and effect on treatment. Clin Infect Dis 2006;42(Suppl 2):S65-71
   PubMed Web of Science ®Google Scholar
• Livermore DM, Woodford N. The beta-lactamase threat in Enterobacteriaceae, Pseudomonas and Acinetobacter. Trends Microbiol 2006;14(9):413-20
   PubMed Web of Science ®Google Scholar
• Galani I, Souli M, Koratzanis E, et al. Emerging bacterial pathogens: Escherichia coli, Enterobacter aerogenes and Proteus mirabilis clinical isolates harbouring the same transferable plasmid coding for metallo-beta-lactamase VIM-1 in Greece. J Antimicrob Chemother 2007;59(3):578-579
   PubMed Web of Science ®Google Scholar
• Karabinis A, Paramythiotou E, Mylona-Petropoulou D, et al. Colistin for Klebsiella pneumoniae-associated sepsis. Clin Infect Dis 2004;38(1):e7-9
   PubMed Web of Science ®Google Scholar
• Bradford PA, Bratu S, Urban C, et al. Emergence of carbapenem-resistant Klebsiella species possessing the class A carbapenem-hydrolyzing KPC-2 and inhibitor-resistant TEM-30 beta-lactamases in New York City. Clin Infect Dis 2004;39(1):55-60
   PubMed Web of Science ®Google Scholar
• Antoniadou A, Kontopidou F, Poulakou G, et al. Colistin-resistant isolates of Klebsiella pneumoniae emerging in intensive care unit patients: first report of a multiclonal cluster. J Antimicrob Chemother 2007;59(4):786-90
   PubMed Web of Science ®Google Scholar
• Rice LB. Challenges in identifying new antimicrobial agents effective for treating infections with Acinetobacter baumannii and Pseudomonas aeruginosa. Clin Infect Dis 2006;43(Suppl 2):S100-5
   PubMed Web of Science ®Google Scholar
• Kawamoto I, Shimoji Y, Kanno O, et al. Synthesis and structure-activity relationships of novel parenteral carbapenems, CS-023 (R-115685) and related compounds containing an amidine moiety. J Antibiot (Tokyo) 2003;56(6):565-79
   PubMed Web of Science ®Google Scholar
• Guignard B, Entenza JM, Moreillon P. Beta-lactams against methicillin-resistant Staphylococcus aureus. Curr Opin Pharmacol 2005;5(5):479-89
   PubMed Web of Science ®Google Scholar
• Thomson KS, Moland ES. CS-023 (R-115685), a novel carbapenem with enhanced in vitro activity against oxacillin-resistant staphylococci and Pseudomonas aeruginosa. J Antimicrob Chemother 2004;54(2):557-62
   PubMed Web of Science ®Google Scholar
• Koga T, Abe T, Inoue H, et al. In vitro and in vivo antibacterial activities of CS-023 (RO4908463), a novel parenteral carbapenem. Antimicrob Agents Chemother 2005;49(8):3239-50
   PubMed Web of Science ®Google Scholar
• Sugihara K, Ishii Y, Tateda K, Yamaguchi K. Carbapenemase stability of CS-023 (RO4908463) and other carbapenems [poster C1-92]. 47th Interscience Conference on Antimicrobial Agents and Chemotherapy; 2007 September 17 – 20; Chicago, IL
   Google Scholar
• Sugihara K, Ishii Y, Tateda K, Yamaguchi K. In vitro activity of CS-023 (RO4908463) against various β-lactamase producing pathogens [poster C2-2055]. 47th Interscience Conference on Antimicrobial Agents and Chemotherapy; 2007 September 17 – 20; Chicago, IL
   Google Scholar
• Zhanel GG, Karlowsky JA, Rubinstein E, Hoban DJ. Tigecycline: a novel glycylcycline antibiotic. Expert Rev Antiinfect Ther 2006;4(1):9-25
   PubMedGoogle Scholar
• Souli M, Kontopidou FV, Koratzanis E, et al. In vitro activity of tigecycline against multiple-drug-resistant, including pan-resistant, gram-negative and gram-positive clinical isolates from Greek hospitals. Antimicrob Agents Chemother 2006;50(9):3166-69
   PubMed Web of Science ®Google Scholar
• Noskin GA, Tigecycline: a new glycylcycline for treatment of serious infections. Clin Infect Dis 2005;41(Suppl 5):S303-14
   PubMed Web of Science ®Google Scholar
• Cobo J, Morosini MI, Pintado V, et al. Use of tigecycline for the treatment of prolonged bacteremia due to a multiresistant VIM-1 and SHV-12 beta-lactamase-producing Klebsiella pneumoniae epidemic clone. Diagn Microbiol Infect Dis 2008;60(3):319-22
   PubMed Web of Science ®Google Scholar
• Pliatsika V, Afkou Z, Protonotariou E, Sofianou D. In vitro activity of tigecycline against metallo-{beta}-lactamase-producing Enterobacteriaceae. J Antimicrob Chemother 2007
   PubMedGoogle Scholar
• Giamarellou H. Treatment options for multidrug-resistant bacteria. Expert Rev Antiinfect Ther 2006;4(4):601-18
   PubMedGoogle Scholar
• Reid GE, Grim SA, Aldeza CA, et al. Rapid development of Acinetobacter baumannii resistance to tigecycline. Pharmacotherapy 2007;27(8):1198-201
   PubMed Web of Science ®Google Scholar
• Peleg AY, Potoski BA, Rea R, et al. Acinetobacter baumannii bloodstream infection while receiving tigecycline: a cautionary report. J Antimicrob Chemother 2007;59(1):128-31
   PubMed Web of Science ®Google Scholar
• Osaki Y, Morinaka A, Mikuniya T, et al. CP3242, a novel metallo-β-lactamase inhibitor: in vitro and in vivo efficacy against clinically isolated metallo-β-lactamase-producing P. aeruginosa [poster F1-332]. 47th Interscience Conference on Antimicrobial Agents and Chemotherapy; 2007 September 17 – 20; Chicago, IL
   Google Scholar
• Zhanel GG, Wiebe R, Dilay L, et al. Comparative review of the carbapenems. Drugs 2007;67(7):1027-52
   PubMed Web of Science ®Google Scholar
• Kahan JS, Kahan FM, Goegelman R, et al. Thienamycin, a new beta-lactam antibiotic. I. Discovery, taxonomy, isolation and physical properties. J Antibiot (Tokyo) 1979;32(1):1-12
   PubMed Web of Science ®Google Scholar
• Norrby SR. Carbapenems. Med Clin North Am 1995;79(4):745-59
   PubMed Web of Science ®Google Scholar
• Lister PD. Carbapenems in the USA: focus on doripenem. Expert Rev Antiinfect Ther 2007;5(5):793-809
   PubMed Web of Science ®Google Scholar
• Moellering RC Jr, Eliopoulos GM, Sentochnik DE: The carbapenems: new broad spectrum beta-lactam antibiotics. J Antimicrob Chemother 1989;24(Suppl A):1-7
   PubMedGoogle Scholar
• Kropp H, Sundelof JG, Hajdu R, Kahan FM. Metabolism of thienamycin and related carbapenem antibiotics by the renal dipeptidase, dehydropeptidase. Antimicrob Agents Chemother 1982;22(1):62-70
   PubMed Web of Science ®Google Scholar
• Norrby SR, Alestig K, Bjornegard B, et al. Urinary recovery of N-formimidoyl thienamycin (MK0787) as affected by coadministration of N-formimidoyl thienamycin dehydropeptidase inhibitors. Antimicrob Agents Chemother 1983;23(2):300-307
   PubMed Web of Science ®Google Scholar
• Birnbaum J, Kahan FM, Kropp H, Macdonald JS. Carbapenems, a new class of beta-lactam antibiotics. Discovery and development of imipenem/cilastatin. Am J Med 1985;78(6A):3-21
   PubMed Web of Science ®Google Scholar
• Sunagawa M, Matsumura H, Inoue T, et al. A novel carbapenem antibiotic, SM-7338 structure-activity relationships. J Antibiot (Tokyo) 1990;43(5):519-32
   PubMed Web of Science ®Google Scholar
• Iso Y, Irie T, Nishino Y, et al. A novel 1 beta-methylcarbapenem antibiotic, S-4661. Synthesis and structure-activity relationships of 2-(5-substituted pyrrolidin-3-ylthio)-1 beta-methylcarbapenems. J Antibiot (Tokyo) 1996;49(2):199-209
   PubMed Web of Science ®Google Scholar
• Edwards JR. Meropenem: a microbiological overview. J Antimicrob Chemother 1995;36(Suppl A):1-17
   PubMed Web of Science ®Google Scholar
• Sumita Y, Fukasawa M, Okuda T. Affinities of SM-7338 for penicillin-binding proteins and its release from these proteins in Staphylococcus aureus. Antimicrob Agents Chemother 1990;34(3):484-6
   PubMed Web of Science ®Google Scholar
• Hashizume T, Ishino F, Nakagawa J, et al. Studies on the mechanism of action of imipenem (N-formimidoylthienamycin) in vitro: binding to the penicillin-binding proteins (PBPs) in Escherichia coli and Pseudomonas aeruginosa, and inhibition of enzyme activities due to the PBPs in E. coli. J Antibiot (Tokyo) 1984;37(4):394-400
   PubMed Web of Science ®Google Scholar
• Kohler J, Dorso KL, Young K, et al. In vitro activities of the potent, broad-spectrum carbapenem MK-0826 (L-749,345) against broad-spectrum beta-lactamase-and extended-spectrum beta-lactamase-producing Klebsiella pneumoniae and Escherichia coli clinical isolates. Antimicrob Agents Chemother 1999;43(5):1170-6
   PubMed Web of Science ®Google Scholar
• Kitzis MD, Acar JF, Gutmann L. Antibacterial activity of meropenem against gram-negative bacteria with a permeability defect and against staphylococci. J Antimicrob Chemother 1989;24(Suppl A):125-32
   PubMedGoogle Scholar
• Jackson JJ, Kropp H, Hurley JC. Influence of antibiotic class and concentration on the percentage of release of lipopolysaccharide from Escherichia coli. J Infect Dis 1994;169(2):471-3
   PubMed Web of Science ®Google Scholar
• Tsuji M, Matsuda H, Miwa H, Miyazaki S. Antimicrobial-induced release of endotoxin from Pseudomonas aeruginosa: comparison of in vitro and animal models. J Antimicrob Chemother 2003;51(2):353-9
   PubMed Web of Science ®Google Scholar
• Bonomo RA, Szabo D. Mechanisms of multidrug resistance in Acinetobacter species and Pseudomonas aeruginosa. Clin Infect Dis 2006;43(Suppl 2):S49-56
   PubMed Web of Science ®Google Scholar
• Vahaboglu H, Ozturk R, Aygun G, et al. Widespread detection of PER-1-type extended-spectrum beta-lactamases among nosocomial Acinetobacter and Pseudomonas aeruginosa isolates in Turkey: a nationwide multicenter study. Antimicrob Agents Chemother 1997;41(10):2265-9
   PubMed Web of Science ®Google Scholar
• Heritier C, Poirel L, Lambert T, Nordmann P. Contribution of acquired carbapenem-hydrolyzing oxacillinases to carbapenem resistance in Acinetobacter baumannii. Antimicrob Agents Chemother 2005;49(8):3198-202
   PubMed Web of Science ®Google Scholar
• Livermore DM. The impact of carbapenemases on antimicrobial development and therapy. Curr Opin Investig Drugs 2002;3(2):218-24
   PubMedGoogle Scholar
• Samra Z, Ofir O, Lishtzinsky Y, et al. Outbreak of carbapenem-resistant Klebsiella pneumoniae producing KPC-3 in a tertiary medical centre in Israel. Int J Antimicrob Agents 2007;30(6):525-9
   PubMed Web of Science ®Google Scholar
• Masuda N, Sakagawa E, Ohya S, et al. Substrate specificities of MexAB-OprM, MexCD-OprJ, and MexXY-oprM efflux pumps in Pseudomonas aeruginosa. Antimicrob Agents Chemother 2000;44(12):3322-7
   PubMed Web of Science ®Google Scholar
• Mushtaq S, Ge Y, Livermore DM. Comparative activities of doripenem versus isolates, mutants, and transconjugants of Enterobacteriaceae and Acinetobacter spp. with characterized beta-lactamases. Antimicrob Agents Chemother 2004;48(4):1313-9
   PubMed Web of Science ®Google Scholar
• Mushtaq S, Ge Y, Livermore DM. Doripenem versus Pseudomonas aeruginosa in vitro: activity against characterized isolates, mutants, and transconjugants and resistance selection potential. Antimicrob Agents Chemother 2004;48(8):3086-92
   PubMed Web of Science ®Google Scholar
• Sakyo S, Tomita H, Tanimoto K, et al. Potency of carbapenems for the prevention of carbapenem-resistant mutants of Pseudomonas aeruginosa: the high potency of a new carbapenem doripenem. J Antibiot (Tokyo) 2006;59(4):220-8
   PubMed Web of Science ®Google Scholar
• Huynh HK, Biedenbach DJ, Jones RN. Delayed resistance selection for doripenem when passaging Pseudomonas aeruginosa isolates with doripenem plus an aminoglycoside. Diagn Microbiol Infect Dis 2006;55(3):241-3
   PubMed Web of Science ®Google Scholar
• Jones RN, Huynh HK, Biedenbach DJ, et al. Doripenem (S-4661), a novel carbapenem: comparative activity against contemporary pathogens including bactericidal action and preliminary in vitro methods evaluations. J Antimicrob Chemother 2004;54(1):144-54
   PubMed Web of Science ®Google Scholar
• Brown SD, Traczewski MM. Comparative in vitro antimicrobial activity of a new carbapenem, doripenem: tentative disc diffusion criteria and quality control. J Antimicrob Chemother 2005;55(6):944-9
   PubMed Web of Science ®Google Scholar
• Chen Y, Garber E, Zhao Q, et al. In vitro activity of doripenem (S-4661) against multidrug-resistant gram-negative bacilli isolated from patients with cystic fibrosis. Antimicrob Agents Chemother 2005;49(6):2510-1
   PubMed Web of Science ®Google Scholar
• Jones RN, Huynh HK, Biedenbach DJ. Activities of doripenem (S-4661) against drug-resistant clinical pathogens. Antimicrob Agents Chemother 2004;48(8):3136-40
   PubMed Web of Science ®Google Scholar
• Fritsche TR, Stilwell MG, Jones RN. Antimicrobial activity of doripenem (S-4661): a global surveillance report 2003. Clin Microbiol Infect 2005;11(12):974-84
   PubMed Web of Science ®Google Scholar
• Kaniga K, Redman R, Llorens L, Friedland I. Prevalence of extended-spectrum beta-lactamase producers (ESBLs) and fluoroquinolone-resistant isolates from phase 3 Trials of complicated urinary tract infections (UTIs) including pyelonephritis [poster E-925]. 47th Interscience Conference on Antimicrobial Agents and Chemotherapy; 2007 September 17 – 20; Chicago, IL
   Google Scholar
• Kaniga K, Umeh O, Llorens L, Friedland I. Activity of doripenem against isolates from phase 3 trials of complicated intra-abdominal infections [poster E-264]. 47th Interscience Conference on Antimicrobial Agents and Chemotherapy; 2007 September 17 – 20; Chicago, IL
   Google Scholar
• Kaniga K, Prokocimer P, Llorens L, Friedland I. Prevalence of extended-spectrum beta-lactamase (ESBL) and fluoroquinolone-resistant isolates from phase 3 trials of nosocomial pneumonia and their susceptibility to doripenem (DOR) [poster E-265]. 47th Interscience Conference on Antimicrobial Agents and Chemotherapy; 2007 September 17 – 20; Chicago, IL
   Google Scholar
• Tsuji M, Ishii Y, Ohno A, et al. In vitro and in vivo antibacterial activities of S-4661, a new carbapenem. Antimicrob Agents Chemother 1998;42(1):94-9
   PubMed Web of Science ®Google Scholar
• Ge Y, Wikler MA, Sahm DF, et al. In vitro antimicrobial activity of doripenem, a new carbapenem. Antimicrob Agents Chemother 2004;48(4):1384-96
   PubMed Web of Science ®Google Scholar
• Goldstein E, Citron DM. In vitro activity of doripenem plus six comparator drugs against 433 aerobic and anaerobic bacteria isolated from infected diabetic foot wounds [poster E-259]. 47th Interscience Conference on Antimicrobial Agents and Chemotherapy; 2007 September 17 – 20; Chicago, IL
   Google Scholar
• Kobayashi Y. Study of the synergism between carbapenems and vancomycin or teicoplanin against MRSA, focusing on S-4661, a carbapenem newly developed in Japan. J Infect Chemother 2005;11(5):259-61
   PubMedGoogle Scholar
• Mushtaq S, Warner M, GE Y, et al. In vitro interactions of doripenem with other antimicrobials [poster E-307]. 45th Interscience Conference on Antimicrobial Agents and Chemotherapy; 2005; Washington, DC
   Google Scholar
• Wexler HM, Engel AE, Glass D, Li C. In vitro activities of doripenem and comparator agents against 364 anaerobic clinical isolates. Antimicrob Agents Chemother 2005;49(10):4413-7
   PubMed Web of Science ®Google Scholar
• Mikamo H, Izumi K, Hua YX, et al. In vitro and in vivo antibacterial activities of a new injectable carbapenem, S-4661, against gynaecological pathogens. J Antimicrob Chemother 2000;46(3):471-4
   PubMed Web of Science ®Google Scholar
• Jones RN, Sader HS, Fritsche TR, Janechek MJ. Selection of a surrogate beta-lactam testing agent for initial susceptibility testing of doripenem, a new carbapenem. Diagn Microbiol Infect Dis 2007
   Google Scholar
• Jones RN, Sader HS, Fritsche TR. Comparative activity of doripenem and three other carbapenems tested against Gram-negative bacilli with various beta-lactamase resistance mechanisms. Diagn Microbiol Infect Dis 2005;52(1):71-4
   PubMed Web of Science ®Google Scholar
• Craig WA. Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. Clin Infect Dis 1998;26(1):1-10; quiz 11-2
   PubMed Web of Science ®Google Scholar
• Burgess DS. Use of pharmacokinetics and pharmacodynamics to optimize antimicrobial treatment of Pseudomonas aeruginosa infections. Clin Infect Dis 2005;40(Suppl 2):S99-104
   PubMed Web of Science ®Google Scholar
• Bhavnani SM, Hammel JP, et al. Use of pharmacokinetic-pharmacodynamic target attainment analyses to support phase 2 and 3 dosing strategies for doripenem. Antimicrob Agents Chemother 2005;49(9):3944-7
   PubMed Web of Science ®Google Scholar
• Kim A, Banevicius MA, Nicolau DP. In vivo efficacy of doripenem human simulated exposures against Pseudomonas aeruginosa [poster A-28a]. 47th Interscience Conference on Antimicrobial Agents and Chemotherapy; 2007 September 17 – 20; Chicago, IL
   Google Scholar
• Nishino N, Otsuki M, Izawa M. In vitro and in vivo antibacterial activity of S-4661, a new carbapenem antibiotic [poster 115]. 36th Interscience Conference on Antimicrobial Agents and Chemotherapy; 1996; New Orleans, LA
   Google Scholar
• Totsuka K, Shiseki M, Uchiyama T, et al. In vitro post-antibiotic effect and in vivo antimicrobial activity of novel carbapenem, S-4661 [poster 113]. 36th Interscience Conference on Antimicrobial Agents and Chemotherapy; 1996; New Orleans, LA
   Google Scholar
• Credito K, Appelbaum PC. Comparative time-kill analysis of the anti-anaerobic activity of doripenem [poster E-261]. 47th Interscience Conference on Antimicrobial Agents and Chemotherapy; 2007 September 17 – 20; Chicago, IL
   Google Scholar
• Simpson AJ, Opal SM, Angus BJ, et al. Differential antibiotic-induced endotoxin release in severe melioidosis. J Infect Dis 2000;181(3):1014-9
   PubMed Web of Science ®Google Scholar
• Doripenem. S 4661. Drugs R&D 2003;4(6):363-5
   PubMedGoogle Scholar
• Ikawa K, Morikawa N, Urakawa N, et al. Peritoneal penetration of doripenem after intravenous administration in abdominal-surgery patients. J Antimicrob Chemother 2007;60(6):1395-7
   PubMed Web of Science ®Google Scholar
• Floren L, Wikler M, Kilfoil T, et al. A phase 1, double-blind, placebo-controlled study to determine the safety, tolerability, and pharmacokinetics of prolonged-infusion regimens of doripenem in healthy subjects [pa-16]. 44th Interscience Conference on Antimicrobial Agents and Chemotherapy; 2004 October 30 – November 2; Washington, DC
   Google Scholar
• Floren L, Wikler M, Kilfoil T, et al. A phase 1 open-label controlled study to evaluate the safety, tolerability, and pharmacokinetics of doripenem administered intravenously to subjects with renal impairment [PA-17]. 44th Interscience Conference on Antimicrobial Agents and Chemotherapy; 2004 October 30 – November 2; Washington, DC
   Google Scholar
• Psathas P, Kuzmission A, Ikeda K, Ihara S. Stability of doripenem for injection (500mg) in representative infusion fluids and containers [abstract 57E]. American Society of Health-System Pharmacists; 2007 June 24 – 27; San Francisco; CA, USA
   Google Scholar
• The official registry of clinical trials of NIH. Available from: http://clinicaltrials.gov/ct2/results?term=doripenem [Accessed on 18 November 2007]
   Google Scholar
• Saito A, Inamatsu T, Shimada J. Clinical studies of S-4661, new parenteral carbapenem antibiotic, in chronic respiratory tract infections [PF-219]. 37th Interscience Conference on Antimicrobial Agents and Chemotherapy; 1997 September 28 – October 1; Toronto
   Google Scholar
• Chastre J, Wunderink R, Prokocimer P, et al. Efficacy and safety of doripenem vs. imipenem for ventilator-associated pneumonia [poster L-486]. 47th Interscience Conference on Antimicrobial Agents and Chemotherapy; 2007 September 17 – 20; Chicago, IL
   Google Scholar
• Solomkin JS, Umeh O, Jiang J, et al. Doripenem vs. meropenem with an option for oral step-down therapy in the treatment of complicated intra-abdominal infections [poster L-487]. 47th Interscience Conference on Antimicrobial Agents and Chemotherapy; 2007 September 17 – 20; Chicago, IL
   Google Scholar
• Réa-Neto Á, Niederman M, Prokocimer P, et al. Efficacy and safety of intravenous doripenem vs. piperacillin/tazobactam in nosocomial pneumonia [poster L-731]. 47th Interscience Conference on Antimicrobial Agents and Chemotherapy; 2007 September 17 – 20; Chicago, IL
   Google Scholar
• Thye D, Kilfoil T, Leighton A, et al. Doripenem: a phase 1 study to evaluate safety, tolerability and pharmacokinetics in a Western healthy volunteer population [pa-21]. 43rd Interscience Conference on Antimicorbial Agents and Chemotherapy; 2003 September 14 – 17; Chicago, IL
   Google Scholar
• Saito A, Inamatsu T, Shimada J. Clinical studies of S-4661, new parenteral carbapenem antibiotic, in chronic respiratory tract infections [PF-219]. 37th Interscience Conference on Antimicrobial Agents and Chemotherapy; 1997 September 28 – October 1; Toronto
   Google Scholar
• Calandra G, Lydick E, Carrigan J, et al. Factors predisposing to seizures in seriously ill infected patients receiving antibiotics: experience with imipenem/cilastatin. Am J Med 1988;84(5):911-8
   PubMed Web of Science ®Google Scholar
• Livermore DM, Sefton AM, Scott GM. Properties and potential of ertapenem. J Antimicrob Chemother 2003;52(3):331-44
   PubMed Web of Science ®Google Scholar
• Linden P. Safety profile of meropenem: an updated review of over 6,000 patients treated with meropenem. Drug Saf 2007;30(8):657-68
   PubMed Web of Science ®Google Scholar
• Lunde JL, Nelson RE, Storandt HF. Acute seizures in a patient receiving divalproex sodium after starting ertapenem therapy. Pharmacotherapy 2007;27(8):1202-5
   PubMed Web of Science ®Google Scholar
• Horiuchi M, Kimura M, Tokumura M, et al. Absence of convulsive liability of doripenem, a new carbapenem antibiotic, in comparison with beta-lactam antibiotics. Toxicology 2006;222(1-2):114-24
   PubMed Web of Science ®Google Scholar
• Nakajima Y, Mizobuchi M, Nakamura M, et al. Mechanism of the drug interaction between valproic acid and carbapenem antibiotics in monkeys and rats. Drug Metab Dispos 2004;32(12):1383-91
   PubMed Web of Science ®Google Scholar
• Job ML, Dretler RH. Seizure activity with imipenem therapy: incidence and risk factors. Dicp 1990;24(5):467-9
   PubMedGoogle Scholar
• Norrby SR, Gildon KM. Safety profile of meropenem: a review of nearly 5,000 patients treated with meropenem. Scand J Infect Dis 1999;31(1):3-10
   PubMed Web of Science ®Google Scholar
• Pestotnik SL, Classen DC, Evans RS, et al. Prospective surveillance of imipenem/cilastatin use and associated seizures using a hospital information system. Ann Pharmacother 1993;27(4):497-501
   PubMed Web of Science ®Google Scholar
• Calandra GB, Wang C, Aziz M, Brown KR. The safety profile of imipenem/cilastatin: worldwide clinical experience based on 3470 patients. J Antimicrob Chemother 1986;18(Suppl E):193-202
   PubMed Web of Science ®Google Scholar
• Prescott WA Jr, Depestel DD, Ellis JJ, Regal RE. Incidence of carbapenem-associated allergic-type reactions among patients with versus patients without a reported penicillin allergy. Clin Infect Dis 2004;38(8):1102-7
   PubMed Web of Science ®Google Scholar
• Sodhi M, Axtell SS, Callahan J, Shekar R. Is it safe to use carbapenems in patients with a history of allergy to penicillin? J Antimicrob Chemother 2004;54(6):1155-7
   PubMed Web of Science ®Google Scholar
• A safety and tolerability study of doripenem in patients with abdominal infections or pneumonia. Available from: http://clinicaltrials.gov/ct2/show/NCT00515034?term=doripenem&rank=1 [Accessed on 18 November 2007]
   Google Scholar
• An effectiveness, safety, and microbiology study of doripenem in patients with nosocomial (hospital-acquired) pneumonia. Available from: http://clinicaltrials.gov/ct2/show/NCT00502801?term=doripenem&rank=7 [Accessed on 18 November 2007]
   Google Scholar
• FDA approves DORIBAX™ for the treatment of complicated intra-abdominal and complicated urinary tract infections. Available from: http://www.ortho-mcneil.com/ortho-mcneil/101507_press_release.html [Accessed on 18 November 2007]
   Google Scholar
• The website of Johnson and Johnson Pharmaceutical. Available from: http://www.jnj.com
   Google Scholar
• Fujimura S, Nakano Y, Sato T, et al. Relationship between the usage of carbapenem antibiotics and the incidence of imipenem-resistant Pseudomonas aeruginosa. J Infect Chemother 2007;13(3):147-50
   PubMed Web of Science ®Google Scholar
• Paul M, Benuri-Silbiger I, Soares-Weiser K, Leibovici L. Beta lactam monotherapy versus beta lactam-aminoglycoside combination therapy for sepsis in immunocompetent patients: systematic review and meta-analysis of randomised trials. BMJ 2004;328(7441):668
   PubMed Web of Science ®Google Scholar
• Safdar N, Handelsman J, Maki DG. Does combination antimicrobial therapy reduce mortality in Gram-negative bacteraemia? A meta-analysis. Lancet Infect Dis 2004;4(8):519-27
   PubMed Web of Science ®Google Scholar
• Giamarellos-Bourboulis EJ. Macrolides beyond the conventional antimicrobials: a class of potent immunomodulators. Int J Antimicrob Agents 2008;31(1):12-20
   PubMed Web of Science ®Google Scholar
• Giamarellos-Bourboulis EJ, Adamis T, Laoutaris G, et al. Immunomodulatory clarithromycin treatment of experimental sepsis and acute pyelonephritis caused by multidrug-resistant Pseudomonas aeruginosa. Antimicrob Agents Chemother 2004;48(1):93-9
   PubMed Web of Science ®Google Scholar
• Giamarellos-Bourboulis EJ, Antonopoulou A, Raftogiannis M, et al. Clarithromycin is an effective immunomodulator when administered late in experimental pyelonephritis by multidrug-resistant Pseudomonas aeruginosa. BMC Infect Dis 2006;6:31
   PubMed Web of Science ®Google Scholar
• Tramper-Stranders GA, Wolfs TF, Fleer A, et al. Maintenance azithromycin treatment in pediatric patients with cystic fibrosis: long-term outcomes related to macrolide resistance and pulmonary function. Pediatr Infect Dis J 2007;26(1):8-12
   PubMed Web of Science ®Google Scholar
• Holder IA, Neely AN, Frank DW. PcrV immunization enhances survival of burned Pseudomonas aeruginosa-infected mice. Infect Immun 2001;69(9):5908-10
   PubMed Web of Science ®Google Scholar
• Baumann U, Mansouri E, Von Specht BU. Recombinant OprF-OprI as a vaccine against Pseudomonas aeruginosa infections. Vaccine 2004;22(7):840-7
   PubMed Web of Science ®Google Scholar
• Baumann U, Gocke K, Gewecke B, et al. Assessment of pulmonary antibodies with induced sputum and bronchoalveolar lavage induced by nasal vaccination against Pseudomonas aeruginosa: a clinical phase I/II study. Respir Res 2007;8:57
   PubMed Web of Science ®Google Scholar
• Digiandomenico A, Rao J, Goldberg JB. Oral vaccination of BALB/c mice with Salmonella enterica serovar Typhimurium expressing Pseudomonas aeruginosa O antigen promotes increased survival in an acute fatal pneumonia model. Infect Immun 2004;72(12):7012-21
   PubMed Web of Science ®Google Scholar
• Lang AB, Rudeberg A, Schoni MH, et al. Vaccination of cystic fibrosis patients against Pseudomonas aeruginosa reduces the proportion of patients infected and delays time to infection. Pediatr Infect Dis J 2004;23(6):504-10
   PubMed Web of Science ®Google Scholar
• Mentzelopoulos SD, Pratikaki M, Platsouka E, et al. Prolonged use of carbapenems and colistin predisposes to ventilator-associated pneumonia by pandrug-resistant Pseudomonas aeruginosa. Intensive Care Med 2007;33(9):1524-32
   PubMed Web of Science ®Google Scholar